Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study

Figure 3

Kaplan-Meyer estimates of time-to progression (a) and overall survival (b) for patients with (solid line) or without (dashed line) central nervous system metastases. Median time to progression was 7.1 and 6.7 months for patients with and without central nervous system involvement, respectively (long-rank test, p = 0.51). Median overall survival was 16.4 and 22.9 months for patients with and without central nervous system involvement, respectively (log-rank test, p = 0.24)

Back to article page